Next Article in Journal
DNA Strand Break Properties of Protoporphyrin IX by X-ray Irradiation against Melanoma
Previous Article in Journal
In or Out? New Insights on Exon Recognition through Splice-Site Interdependency
Previous Article in Special Issue
MicroRNA-451 and Genistein Ameliorate Nonalcoholic Steatohepatitis in Mice
Open AccessReview

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)

by Kyeongjin Kim 1,* and Kook Hwan Kim 2,*
1
Department of Biomedical Sciences, College of Medicine, Inha University, Inha-ro 100, Michuhol-gu, Incheon 22212, Korea
2
Metabolic Diseases Research Center, GI Cell, Inc., B-1014, Tera Tower, Songpa-daero 167, Songpa-gu, Seoul 05855, Korea
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(7), 2296; https://doi.org/10.3390/ijms21072296
Received: 6 March 2020 / Revised: 24 March 2020 / Accepted: 25 March 2020 / Published: 26 March 2020
Nonalcoholic steatohepatitis (NASH) is defined as a progressive form of nonalcoholic fatty liver disease (NAFLD) and is a common chronic liver disease that causes significant worldwide morbidity and mortality, and has no approved pharmacotherapy. Nevertheless, growing understanding of the molecular mechanisms underlying the development and progression of NASH has suggested multiple potential therapeutic targets and strategies to treat this disease. Here, we review this progress, with emphasis on the functional role of secretory proteins in the development and progression of NASH, in addition to the change of expression of various secretory proteins in mouse NASH models and human NASH subjects. We also highlight secretory protein-based therapeutic approaches that influence obesity-associated insulin resistance, liver steatosis, inflammation, and fibrosis, as well as the gut–liver and adipose–liver axes in the treatment of NASH. View Full-Text
Keywords: NAFLD; NASH; secretory proteins NAFLD; NASH; secretory proteins
Show Figures

Figure 1

MDPI and ACS Style

Kim, K.; Kim, K.H. Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH). Int. J. Mol. Sci. 2020, 21, 2296.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop